Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more
Cadrenal Therapeutics, Inc. Common Stock (CVKD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.862x
Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a cash flow conversion efficiency ratio of -0.862x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Million) by net assets ($2.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cadrenal Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Electromagnetica SA
RO:ELMA
|
0.031x |
|
Seojin Automotive Co.Ltd
KQ:122690
|
-0.029x |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
-0.075x |
|
JG Environmental Technology Co.,Ltd.
TWO:6723
|
0.171x |
|
Medicus Pharma Ltd. Common Stock
OTCBB:MDCX
|
8.396x |
|
Initiator Pharma A/S
ST:INIT
|
-0.144x |
|
Akobo Minerals AB (publ)
OL:AKOBO
|
0.133x |
|
The INX Digital Company Inc.
OTCQB:INXDF
|
-0.333x |
Annual Cash Flow Conversion Efficiency for Cadrenal Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.44 Million | $-7.36 Million | -0.989x | -115.49% |
| 2023-12-31 | $7.69 Million | $-3.53 Million | -0.459x | -311.46% |
| 2022-12-31 | $-5.55 Million | $-1.20 Million | 0.217x | -- |